Silence Therapeutics (SLN) Competitors $5.12 +0.09 (+1.79%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends SLN vs. BCAX, DNTH, CRMD, QURE, ETNB, CGEM, LENZ, PHAR, ABUS, and IMNMShould you be buying Silence Therapeutics stock or one of its competitors? The main competitors of Silence Therapeutics include Bicara Therapeutics (BCAX), Dianthus Therapeutics (DNTH), CorMedix (CRMD), uniQure (QURE), 89bio (ETNB), Cullinan Therapeutics (CGEM), LENZ Therapeutics (LENZ), Pharming Group (PHAR), Arbutus Biopharma (ABUS), and Immunome (IMNM). These companies are all part of the "pharmaceutical products" industry. Silence Therapeutics vs. Bicara Therapeutics Dianthus Therapeutics CorMedix uniQure 89bio Cullinan Therapeutics LENZ Therapeutics Pharming Group Arbutus Biopharma Immunome Bicara Therapeutics (NASDAQ:BCAX) and Silence Therapeutics (NASDAQ:SLN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation. Does the MarketBeat Community believe in BCAX or SLN? Silence Therapeutics received 32 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 81.25% of users gave Silence Therapeutics an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes7100.00% Underperform VotesNo VotesSilence TherapeuticsOutperform Votes3981.25% Underperform Votes918.75% Is BCAX or SLN more profitable? Bicara Therapeutics has a net margin of 0.00% compared to Silence Therapeutics' net margin of -342.00%. Bicara Therapeutics' return on equity of 0.00% beat Silence Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Silence Therapeutics -342.00%-62.81%-33.89% Which has higher earnings and valuation, BCAX or SLN? Bicara Therapeutics has higher earnings, but lower revenue than Silence Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/ASilence Therapeutics$31.55M4.86-$53.82M-$1.57-3.26 Do analysts rate BCAX or SLN? Bicara Therapeutics presently has a consensus price target of $43.00, suggesting a potential upside of 255.08%. Silence Therapeutics has a consensus price target of $57.20, suggesting a potential upside of 1,017.19%. Given Silence Therapeutics' higher possible upside, analysts clearly believe Silence Therapeutics is more favorable than Bicara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Silence Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer BCAX or SLN? In the previous week, Bicara Therapeutics had 3 more articles in the media than Silence Therapeutics. MarketBeat recorded 4 mentions for Bicara Therapeutics and 1 mentions for Silence Therapeutics. Silence Therapeutics' average media sentiment score of 0.93 beat Bicara Therapeutics' score of 0.66 indicating that Silence Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Silence Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in BCAX or SLN? 98.7% of Silence Therapeutics shares are owned by institutional investors. 3.0% of Silence Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryBicara Therapeutics beats Silence Therapeutics on 7 of the 13 factors compared between the two stocks. Get Silence Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLN vs. The Competition Export to ExcelMetricSilence TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$153.24M$6.58B$5.36B$9.13BDividend YieldN/A2.95%5.13%4.03%P/E Ratio-3.269.8389.4717.33Price / Sales4.86308.061,264.56137.35Price / CashN/A61.4443.7535.97Price / Book7.216.055.324.80Net Income-$53.82M$154.62M$122.60M$224.91M7 Day Performance-14.52%-1.68%0.69%1.77%1 Month Performance-21.35%-2.35%1.55%2.22%1 Year Performance-71.68%1.02%27.25%20.67% Silence Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLNSilence Therapeutics2.7108 of 5 stars$5.12+1.8%$57.20+1,017.2%-71.8%$153.24M$31.55M-3.26100News CoverageHigh Trading VolumeBCAXBicara TherapeuticsN/A$12.97-9.8%$43.00+231.5%N/A$705.78MN/A0.0032News CoverageDNTHDianthus Therapeutics1.6745 of 5 stars$23.13-4.4%$46.43+100.7%+56.8%$684.58M$5.37M-9.2580Short Interest ↑CRMDCorMedix2.3694 of 5 stars$11.12-0.6%$15.67+40.9%+280.7%$674.73M$12.26M-13.7330QUREuniQure3.8959 of 5 stars$13.77-0.6%$33.88+146.0%+141.7%$671.19M$28.59M-2.78500Short Interest ↓ETNB89bio1.8946 of 5 stars$6.31-3.1%$30.33+380.7%-45.0%$669.66MN/A-2.1740Short Interest ↑News CoverageCGEMCullinan Therapeutics2.3921 of 5 stars$11.09-0.9%$31.67+185.5%-3.2%$645.75M$18.94M-3.9030LENZLENZ Therapeutics1.8874 of 5 stars$23.45+1.0%$35.40+51.0%N/A$644.90MN/A0.00110Short Interest ↑Positive NewsPHARPharming Group2.5534 of 5 stars$9.37-3.5%$27.00+188.2%-25.0%$635.61M$285.75M-36.04280Short Interest ↑Positive NewsGap DownABUSArbutus Biopharma2.7419 of 5 stars$3.35+1.8%$5.50+64.2%+42.5%$634.80M$6.74M-7.7973Positive NewsIMNMImmunome1.6414 of 5 stars$10.06-5.1%$28.83+186.6%-29.4%$627.92M$10.13M-1.2440Short Interest ↑ Related Companies and Tools Related Companies BCAX Alternatives DNTH Alternatives CRMD Alternatives QURE Alternatives ETNB Alternatives CGEM Alternatives LENZ Alternatives PHAR Alternatives ABUS Alternatives IMNM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SLN) was last updated on 1/17/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silence Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Silence Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SLN Stock Alerts